Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 2—February 2020
Research

Chronic Human Pegivirus 2 without Hepatitis C Virus Co-infection

Kelly E. CollerComments to Author , Veronica Bruce, Michael Cassidy, Jeffrey Gersch, Matthew B. Frankel, Ana Vallari, Gavin Cloherty, John Hackett, Jennifer L. Evans, Kimberly Page, and George J. Dawson
Author affiliations: Abbott Laboratories, Abbott Park, Illinois, USA (K.E. Coller, M. Cassidy, J. Gersch, M.B. Frankel, A. Vallari, G. Cloherty, J. Hackett, Jr., G.J. Dawson); University of New Mexico, Albuquerque, New Mexico, USA (V. Bruce, K. Page); University of California San Francisco, San Francisco, California, USA (J.L. Evans)

Main Article

Table 3

Information about participants with HPgV-2 infection with HCV co-infection in study of injection drug users in the San Francisco Bay area, California, USA*

Sample ID Participant age, y/sex No. years drug use† Collection date HCV RNA HCV antibody NS2/3 log10 copies/mL 5′ UTR log10 copies/mL NS4AB S/CO‡ E2 S/CO‡
RM0337 25.6/F 11.1 2013 Jul 10 Neg Neg Neg Neg 0.16 0.14
2013 Oct 9 Neg Neg Neg Neg 0.14 0.13
2014 Jan 29 Neg Neg Neg Neg 0.13 0.12
2016 Jul 27 Neg Neg Neg Neg 0.12 0.11
2016 Oct 26 Neg Neg Neg Neg 0.12 0.13
2017 Jan 18 Neg Neg Neg Neg 0.13 0.13
2017 Apr 26 Neg Neg 0.96 0.42 0.13 1.46
2017 Jul 19 Neg Neg Neg Neg 0.09 1.34
2017 Oct 18 Neg Neg Neg Neg 0.13 0.88
2018 Jan 31 Pos Neg Neg Neg 0.14 1.02
2018 Feb 14
 Pos
 Neg
 Neg
 Neg
 0.25
 1.26
VH0085§ 22.2/F 9.9 2010 May 14 Pos Pos 3.22 2.3 1.38 9.37
2017 Feb 15 Neg Not tested 3.14 2.07 2.96 12.92
2017 May 17 Neg Not tested 1.87 0.69 3.33 12.35
2017 Aug 9 Neg Not tested 4.30 2.25 6.13 18.71
2017 Nov 1 Neg Not tested 3.40 1.68 5.13 19.45
2018 Jan 17
 Neg
 Not tested
 3.86
 2.26
 3.75
 16.16
GG0038§ 26.5/M 8.8 2016 Jul 14 Pos Pos Neg Neg 0.16 0.12
2017 Mar 1 Pos Not tested 3.04 1.02 0.17
2017 May 3 Pos Not tested 2.14 0.64 0.20 0.37
2017 May 23 Neg Not tested 3.01 1.16 0.18 0.36
2017 Oct 18
 Neg
 Not tested
 4.15
 1.91
 0.16
 2.96
VT0031 19.8/M 1.8 2005 Feb 2 Pos Pos Neg Neg 0.09 0.22
2005 May 24 Pos Pos Neg Neg 0.11 0.15
2005 Jun 14 Pos Pos Neg Neg 0.10 0.17
2005 Aug 9 Pos Pos Neg Neg 0.12 0.14
2005 Nov 8 Pos Pos Neg Neg 0.08 0.13
2006 Jan 31 Pos Pos Neg Neg 0.14 0.13
2006 May 9 Pos Pos Neg Neg 0.09 0.19
2006 Aug 8 Pos Pos Neg Neg 0.21 1.25
2007 Feb 6 Pos Pos 2.30 0.53 0.14 1.19
2007 May 1 Pos Pos 0.48 0.41 0.14 1.82

*Participants were determined positive for HCV by RNA or antibody test. HCV, hepatitis C virus; HPgV-2, human pegivirus 2; ID, identification; neg, negative; NS, nonstructural protein; pos, positive; S/CO, signal to cutoff value; UTR, untranslated region.
†Number of years participant had injected drugs as of the time of the initial blood draw.
‡S/CO >1.0 is considered positive.
§Participants VH0085 and GG0038 demonstrate resolved HCV infection. VH0085 was administered direct active antiviral drugs (8 weeks ledipasvir/sofosbuvir, LDV-SOF), and GG0038 spontaneously cleared HCV infection.
¶Volume not available for testing.

Main Article

Page created: January 17, 2020
Page updated: January 17, 2020
Page reviewed: January 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external